EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Tegoprazan as First‐ and Second‐Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta‐Analysis

Sujata Purja iD, Yousong Lee, Eunyoung Kim iD

Journal of Digestive Diseases · 2025-07 · 26 (7-8) · 305-317

DOI: 10.1111/1751-2980.70004 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Digestive Diseases, online erschienen am 18.08.2025. Verfasst von Sujata Purja und 2 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang Un…. Hauptthemen laut MEDLINE: Helicobacter Infections, Proton Pump Inhibitors, Helicobacter pylori. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chung-Ang University Research Scholarship in 2025, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of tegoprazan (TPZ) compared to conventional proton pump inhibitors (PPIs) for Helicobacter pylori eradication as first‐ and second‐line therapies.

Methods

Four databases were searched for randomized controlled trials (RCTs) and retrospective studies comparing TPZ‐ and PPI‐based regimens for H. pylori eradication published until October 15, 2024. A random‐effects model was used to calculate pooled odds ratio (OR) and 95% confidence interval (CI) based on intention‐to‐treat and per‐protocol analyses. The PROSPERO registration number of the study is CRD42024622705.

Results

Nine studies (three RCTs and six retrospective studies) involving 5228 treatment‐naïve patients were included. TPZ was non‐inferior to PPIs as a first‐line therapy (intention‐to‐treat: odds ratio [OR] 1.066, 95% confidence interval [CI] 0.929–1.224; per‐protocol: OR 1.142, 95% CI: 0.967–1.349). Subgroup analyses showed no significant differences based on study design, therapeutic regimen, or treatment duration. In patients with clarithromycin‐resistant strains confirmed by 23S rRNA sequencing, TPZ achieved a higher eradication rate (OR 4.961, 95% CI 1.024–24.030). TPZ was associated with significantly lower odds of abdominal discomfort compared to PPIs (OR 0.490, 95% CI 0.268–0.897). Regarding treatment duration, a 14‐day regimen was linked to a lower risk of diarrhea, while a 7‐day regimen was associated with a higher risk of abdominal pain. No significant differences were observed in second‐line therapeutic outcomes.

Conclusions

TPZ represents a non‐inferior alternative to PPIs for H. pylori eradication, with potential benefits in clarithromycin‐resistant infections and favorable safety profiles. Future studies are warranted to assess higher dosages and address pharmacokinetic limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsProton Pump InhibitorsHelicobacter pyloriHumansAnti-Bacterial AgentsRandomized Controlled Trials as TopicTreatment OutcomeDrug Therapy, CombinationPyrrolesSulfonamides

Stichwörter der Autor:innen

Helicobacter pyloriclarithromycin resistancemeta‐analysisproton pump inhibitorstegoprazan

Substanzen

Proton Pump InhibitorsAnti-Bacterial Agents1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamides

Autor:innen und Institutionen

  • Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Central Research Centre of Epigenome Based Platform and Its Application for Drug Development, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Regulatory Science Policy, Pharmaceutical Regulatory Sciences, Chung-Ang University, Seoul, Republic of Korea.

ORCID-Profile: Sujata Purja, Eunyoung Kim

Förderung

  • Chung-Ang University Research Scholarship in 2025
  • National Research Foundation of Korea

Zitieren

APA

Purja, S., Lee, Y., & Kim, E. (2025). Tegoprazan as First‐ and Second‐Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta‐Analysis. Journal of Digestive Diseases, 26(7-8), 305-317. https://doi.org/10.1111/1751-2980.70004

Vancouver

Purja S, Lee Y, Kim E. Tegoprazan as First‐ and Second‐Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta‐Analysis. Journal of Digestive Diseases. 2025;26(7-8):305-317. doi:10.1111/1751-2980.70004

BibTeX
@article{Purja2025,
  author = {Purja, Sujata and Lee, Yousong and Kim, Eunyoung},
  title = {Tegoprazan as First‐ and Second‐Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta‐Analysis},
  journal = {Journal of Digestive Diseases},
  year = {2025},
  volume = {26},
  number = {7-8},
  pages = {305--317},
  doi = {10.1111/1751-2980.70004}
}
Kostenlos starten →